Mélissa Bowerman

Mifepristone alone and in combination with scAAV9-SMN1 gene therapy improves disease phenotypes in Smn2B/- spinal muscular atrophy mice

This study shows that mifepristone, a glucocorticoid antagonist, improves SMA disease phenotypes in mice, both alone and when combined with SMN gene therapy.

Exercise and disease state influence the beneficial effects of Fn14-depletion on survival and muscle pathology in the SOD1G93A amyotrophic lateral sclerosis (ALS) mouse model

This study shows that Fn14-depletion improves survival and muscle pathology in SOD1G93A ALS mice, but only when combined with exercise.

Defining an Ageing-Related Pathology, Disease or Syndrome: International Consensus Statement

The paper establishes international consensus criteria to classify ageing-related pathologies, diseases, and syndromes based on age progression, functional decline, and human evidence.

Differential effect of Fas activation on spinal muscular atrophy motoneuron death and induction of axonal growth

This study shows Fas activation induces both death and axonal growth in motoneurons, with distinct molecular pathways involved in each response.

Combining multi-omics and drug perturbation profiles to identify novel treatments that improve disease phenotypes in spinal muscular atrophy

This study identifies novel drug treatments for spinal muscular atrophy by integrating multi-omics data and drug perturbation profiles, showing harmine improves disease phenotypes in models.